The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
ORGANIZATION
Experts Eye Macroeconomic Indexing of Drug Costs to Keep Innovation Afloat: INES Proposal
A group of economists has drawn up a proposal on the Japanese drug pricing system, calling for the introduction of “macroeconomic indexing” for pharmaceutical costs to contain fiscal volatility without strangling innovation. The idea is to set a certain cap…
To read the full story
Related Article
- Main Focus of INES Proposal Is Securing Resources to Reward Innovation, Not Macroeconomic Indexing
October 25, 2021
- JPMA Chief Opposes Macroeconomic Indexing, Says Drugs Should Drive Economic Growth
September 22, 2021
- Attention Grows for INES Drug Pricing Proposal; Will It Become Next Card on Reform?
July 12, 2021
ORGANIZATION
- EFPIA Japan, Patient Groups Call for Stronger Health Literacy, PPI
December 22, 2025
- JPMA Exec Renews Call for Simpler Drug Pricing System
December 19, 2025
- JGA to Create “Stable Supply Network” Membership to Expand Ramp-Up Scheme
December 18, 2025
- Pharma Groups Reiterate “No” to Broader CEA Use, Huge-Seller and Spillover Rules: Joint Statement
December 17, 2025
- Japan Medical Societies Recommend RSV Vaccination for Older Adults
December 15, 2025
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…